Kjaer SK, et al. - Researchers sought to assess the long-term effectiveness of the quadrivalent human papillomavirus (qHPV) vaccine by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ (AIS), and cervical cancer related to HPV16 or HPV18. In women, the qHPV vaccine demonstrated continued protection through at least 10 years, with a trend for continued protection through 12 years of follow-up.